Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience

Table 1

Patient characteristics and response to treatment.

Case Number	1	2	3	4	5	6	7	8	9
DOB	1942	1947	1930	1956	1930	1942	1924	1959	1955
Gender	Male	Male	Male	Male	Female	Male	Female	Female	Female
Comorbidities	CAD, AH	AH, BPH	CAD, peptic ulcer	AH, NSCLC, abdominal aneurysm	Dementia, thyroid goiter	AH, thoracic aneurysm	Hypothyroidism, glaucoma	Ankylosing spondylitis	Nonsignificant
MPN	Pre-fibrotic PMF	PV	MDS/MPN-RS-T	PMF	Pre-fibrotic PMF	MDS/MPN-RS-T	MDS/MPN-RS-T	PMF	Post-ET MF
JAK2 V617F	Positive	Positive	Negative	Positive	Positive	Negative	Negative	Positive	Positive
MPN treatment	Observation	Hydroxycarba mide, bloodlettings	Epoetin alpha, RBC transfusions	Hydroxycarbamide, bloodlettings	Hydroxycarbamide	Epoetin alfa, RBC transfusions	Epoetin alpha, RBC transfusions	Ruxolitinib	Hydroxycarbamide
Age at MPN	74	67	84	60	85	74	85	53	59
LPD	MBL	B-CLL	B-CLL	MZL	MM	PBL	B CLL	Splenic MZL	LHCDD
Age at LPD	74	70	86	50	86	76	93	57	63
LPD treatment	Observation	Obinutuzumab/Chlorambucil	Observation	Splenectomy, Rituximab	Lenalidomide	Bortezomib-CHOP	Obinutuzumab/Chlorambucil	RCOP	VCD
LPD treatment outcome	NA	CR	NA	PR	Intolerance	CR	Intolerance	CR	CR

DOB: Date of birth, MBL: Monoclonal B-cell lymphocytosis, MF: Myelofibrosis, B-CLL: B chronic lymphocytic leukemia, MM: Multiple myeloma, LHCDD: Light and heavy chain deposistion disease RBC: Red blood cell, MDS/MPN RS-T: Myelodysplastic syndromes/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis, CAD: Coronary artery disease, AH: Arterial hypertension, BPH: Benign prostate hyperplasia, NSCLC: NonSmall cell lung carcinoma, CR: Complete response, PR: partial response, MZL: Marginal zone lymphoma, PBL: Plasmablastic lymphoma, VCD: Bortezomib, cyclophosphamide, dexamethasone, RCOP: Rituximab cyclophosphamide vincristine prednisolone CHOP: Cyclophosphamide, doxorubicin, vincristine, prednisolone, NA: Nonapplicable.